Corcept Therapeutics Inc. (Corcept) is a commercial-stage biopharmaceutical company that discovers, develops, and markets therapies for severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company’s research centers on conditions driven by dysregulation of the steroid hormone cortisol and signaling through the glucocorticoid receptor. Corcept’s scientific premise is that excess or abnormal cortisol activity can suppress immune surveillance that helps prevent oncogenesis, protect certain tumor cells from chemotherapy-induced apoptosis, and promote the growth of others. By designing selective cortisol modulators, Corcept aims to restore physiologic balance and improve outcomes across multiple cortisol-associated diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Corcept is actively engaged in developing selective cortisol modulators for various medical conditions. The company's proprietary compound, relacorilant, is being developed for the treatment of hypercortisolism and is undergoing trials for its efficacy in oncology, particularly in platinum-resistant ovarian cancer and prostate cancer. It is also exploring the potential of relacorilant in combination with other therapies to enhance anti-cancer treatments. Additionally, Corcept is investigating dazucorilant for ALS and miricorilant for metabolic dysfunction-associated steatohepatitis (MASH). The company is conducting multiple clinical trials across different phases to evaluate the safety and efficacy of these compounds. The R&D unit is responsible for managing the company's research and development activities, including the design and execution of clinical trials, the development of new therapeutic compounds, and the exploration of potential new indications for existing compounds. In FY2025, the company spent US$254.9 million on its R&D, which as a percentage of revenue stood 33.4%, and grew 3.2%.